Publication Name	World Journal of Diabetes
Manuscript ID	14018
Country	Finland

Received	2014-09-14 12:47
Peer-Review Started	2014-09-14 16:17
To Make the First Decision	2014-11-14 18:46
Return for Revision	2014-11-19 17:05
Revised	2014-12-22 22:42
Second Decision	2015-03-11 13:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-03-20 10:23
Articles in Press	2015-03-20 10:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-22 15:38
Publish the Manuscript Online	2015-07-10 18:24

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Serum hepcidin concentrations and type 2 diabetes
Manuscript Source	Invited Manuscript
All Author List	Alex Aregbesola, Sari Voutilainen, Jyrki K Virtanen, Adeola Aregbesola and Tomi-Pekka Tuomainen
Funding Agency and Grant Number
Corresponding Author	Alex Aregbesola, MD, MScPH, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Yliopistonranta 1C, PO Box 1627, FI70211 Kuopio, Finland. alex.aregbesola@uef.fi
Key Words	Serum hepcidin; Body iron; Diabetes; Type 2 diabetes; Insulin resistance
Core Tip	Excess body iron has been demonstrated as an independent risk factor of type 2 diabetes (T2D). Lately, manipulation of serum hepcidin concentrations through the use of hepcidin agonist is being suggested in the management of iron overload diseases, of which T2D is one. However, little is known about the role of hepcidin in the development of T2D; hence, the need for a review of the existing evidence linking hepcidin and T2D. We discuss some of the main mechanisms through which hepcidin could be associated with T2D.
Publish Date	2015-07-10 18:24
Citation	Aregbesola A, Voutilainen S, Virtanen JK, Aregbesola A, Tuomainen TP. Serum hepcidin concentrations and type 2 diabetes. World J Diabetes 2015; 6(7): 978-982
URL	http://www.wjgnet.com/1948-9358/full/v6/i7/978.htm
DOI	http://dx.doi.org/10.4239/wjd.v6.i7.978

Full Article (PDF)	WJD-6-978.pdf
Full Article (Word)	WJD-6-978.doc
Manuscript File	14018-Review.doc
Answering Reviewers	14018-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	14018-Conflict-of-interest statement.pdf
Copyright License Agreement	14018-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	14018-Language certificate.pdf
Peer-review Report	14018-Peer-review(s).pdf
Scientific Misconduct Check	14018-Scientific misconduct check.pdf
Scientific Editor Work List	14018-Scientific editor work list.pdf